Business Wire·Apr 7, 2026, 8:00 AM ET

bioAffinity Technologies' CyPath® Lung to Be Featured at Cleveland Clinic Annual "Advances in Early Lung Cancer Detection" Symposium April 16

bioAffinity Technologies announces its CyPath® Lung test will be featured at the "Advances in Early Lung Cancer Detection" symposium at the Cleveland Clinic on April 16, 2026.
Chief Medical Officer Gordon Downie, MD, PhD, will participate as a panelist discussing lung nodule management & the benefits of CyPath® Lung for high-risk patients.
This marks the seventh annual symposium & bioAffinity Technologies' seventh invitation to present before global lung cancer leaders.
The agenda covers lung cancer risk assessment, emerging diagnostics, screening biomarkers, AI, & the changing epidemiology of lung cancer.
Dr. Downie states CyPath® Lung serves as a noninvasive adjunct to standard care for indeterminate pulmonary nodules to guide decisions, accelerate diagnosis, & reduce unnecessary invasive procedures.
CyPath® Lung utilizes flow cytometry & AI to analyze sputum samples for cancer-related cells using a fluorescent porphyrin preferentially taken up by malignant cells.
Clinical data indicates the test achieved 92% sensitivity, 87% specificity, & 88% accuracy in detecting lung cancer in patients with indeterminate nodules under 20 millimeters.
The test supports clinical decision-making for high-risk patients regardless of nodule size or cancer history & can also monitor lung cancer survivors for recurrence.
CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies, under CLIA oversight.